3 -0.18 (-5.66%) | 03-28 16:00 | |||||||||||||
|
|
Short term | ||||
Mid term | ||||
Targets | 6-month : | 3.71 | 1-year : | 4.33 |
Resists | First : | 3.18 | Second : | 3.71 |
Pivot price | 2.8 | |||
Supports | First : | 2.75 | Second : | 2.5 |
MAs | MA(5) : | 2.95 | MA(20) : | 2.83 |
MA(100) : | 2.48 | MA(250) : | 1.93 | |
MACD | MACD : | 0 | Signal : | -0.1 |
%K %D | K(14,3) : | 76 | D(3) : | 67.1 |
RSI | RSI(14): 53.4 | |||
52-week | High : | 3.52 | Low : | 1.11 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GLYC ] has closed below upper band by 24.3%. Bollinger Bands are 17.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 3.11 - 3.13 | 3.13 - 3.14 |
Low: | 2.86 - 2.88 | 2.88 - 2.9 |
Close: | 2.97 - 3 | 3 - 3.03 |
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as in phase 3 trial to treat relapsed/refractory AML. In addition, the company is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. It also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Thu, 28 Mar 2024
Is it Time to Dump GlycoMimetics Inc (GLYC) Stock After it Is Up 4.86% in a Week? - InvestorsObserver
Thu, 28 Mar 2024
GlycoMimetics, Inc. (NASDAQ:GLYC) Q4 2023 Earnings Call Transcript - Yahoo Finance
Thu, 28 Mar 2024
HC Wainwright Weighs in on GlycoMimetics, Inc.'s FY2026 Earnings (NASDAQ:GLYC) - MarketBeat
Thu, 28 Mar 2024
GlycoMimetics Full Year 2023 Earnings: US$0.58 loss per share (vs US$0.89 loss in FY 2022) - Simply Wall St
Thu, 28 Mar 2024
GlycoMimetics' (GLYC) Buy Rating Reaffirmed at HC Wainwright - Defense World
Wed, 27 Mar 2024
GlycoMimetics Inc (GLYC) Posts Quarterly Loss, Aligns with Analyst Projections - Yahoo Finance
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 64 (M) |
Shares Float | 40 (M) |
Held by Insiders | 3 (%) |
Held by Institutions | 53.5 (%) |
Shares Short | 1,560 (K) |
Shares Short P.Month | 998 (K) |
EPS | -0.63 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0.72 |
Profit Margin | 0 % |
Operating Margin | 0 % |
Return on Assets (ttm) | -46.2 % |
Return on Equity (ttm) | -80.5 % |
Qtrly Rev. Growth | 0 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | 0 |
EBITDA (p.s.) | -0.63 |
Qtrly Earnings Growth | 0 % |
Operating Cash Flow | -35 (M) |
Levered Free Cash Flow | -23 (M) |
PE Ratio | -4.77 |
PEG Ratio | 0 |
Price to Book value | 4.16 |
Price to Sales | 0 |
Price to Cash Flow | -5.5 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |